Use of triamcinolone and bevacizumab in 25G phaco-vitrectomy surgery for the treatment of cataract and diabetic macular edema;Uso de triamcinolona y bevacizumab en cirugía de faco-vitrectomía 25G para el tratamiento de catarata y edema macular diabético

Archivos de la Sociedad Espanola de Oftalmologia

Volumn 83, Issue 5, 2008, Pages 293-300

  Hernández Da Mota, Sergio Eustolio ^a,b   Chacon Lara A ^a   Hernandez Vazquez E ^a  

^a Clinica David   (Mexico)

^b Retina Clinic   (Mexico)

Author keywords

Bevacizumab; Cataract; Phacoemulsification; Triamcinolone; Vitrectomy

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; GLUCOCORTICOID; MONOCLONAL ANTIBODY; TRIAMCINOLONE;

ADULT; AGED; ARTICLE; CATARACT; CLINICAL TRIAL; DIABETIC RETINOPATHY; DRUG COMBINATION; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PHACOEMULSIFICATION; PROSPECTIVE STUDY; RETINA MACULA EDEMA; VITRECTOMY;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CATARACT; COMBINED MODALITY THERAPY; DIABETIC RETINOPATHY; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; MACULAR EDEMA; MALE; MIDDLE AGED; PHACOEMULSIFICATION; PROSPECTIVE STUDIES; TRIAMCINOLONE; VITRECTOMY;

EID: 45849092898     PISSN: 03656691     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. Diabetes Control and Complications Trial Research Group. N Eng J Med 1993; 329: 977-986.
2. The relationship on glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 1995; 44: 968-983.
3. The absence of a glycemic threshold for the development of long term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 1996; 45: 1289-1298.
4. Flesner P, Sander B, Henning V, Parving HH, Dornonville de la Cour M, Lund-Andersen H. Cataract surgery on diabetic patients. A prospective evaluation of risk factors and complications. Acta Ophthalmol Scand 2002; 80: 19-24.
5. Gupta A, Gupta V. Diabetic maculopathy and cataract surgery. Ophthalmol Clin North Am 2001; 14: 625-637.
6. Squirrell D, Bhola R, Bush J, Winder S, Talbot JF. A prospective, case controlled study of the natural history of diabetic retinopathy and maculopathy after uncomplicated phacoemulsification cataract surgery in patients with type 2 diabetes. Br J Ophthalmol 2002; 86: 565-571.
7. Photocoagulation for diabetic macular edema Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study Research Group. Arch Ophthalmol 1985; 103: 1796-1806.
8. Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report no. 4. Early Treatment Diabetic Retinopathy Study Research Group. Int Ophthalmol Clin 1987; 27: 265-272.
9. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1987; 94: 761-774.
10. Han DP, Miller WF, Burton TC. Submacular fibrosis after photocoagulation for diabetic macular edema. Am J Ophthalmol 1992; 113: 513-521.
11. Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002; 109:920-927.
12. Jonas JB, Kreissig I, Söfker A, Degenring RF. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol 2003; 121: 57-61.
13. Massin P, Audren F, Haouchine B , Erginay A, Bergmann JF, Benosman R, et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology 2004; 111: 218-225.
14. Sakamoto T, Miyazaki M, Hisatomi T, Nakamura T, Ueno A, Itaya K, et al. Triamcinolone-assisted pars plana vitrectomy improves the surgical procedures and decreases the postoperative blood-ocular barrier breakdown. Graefes Arch Clin Exp Ophthalmol 2002; 240: 423-429.
15. Pinheiro A, Serracarbassa PD, Maia OO Jr, Takahashi WY. Macular thickness analysis by optic coherence tomography in refractory diabetic macular edema treated with intravitreous triamcinolone. Arq Bras Oftalmol 2007; 70: 784-789.
16. Ciardella AP, Klancnik J, Schiff W, Barile G, Langton K, Chang S. Intravitreal triamcinolone for the treatment of refractory diabetic macular oedema with hard exudates: an optical coherence tomography study. Br J Ophthalmol 2004; 88: 1131-1136.
17. Jonas JB, Kreissig I, Degenring RF, Kamppeter BA. Repeated intravitreal injection of triamcinolone acetonide for diffuse diabetic macular oedema. Br J Ophthalmol 2005; 89: 122.
18. Gómez-Ulla F, Marticorena J, Alfaro DV 3rd, Fernández M, Méndez ER, Rothen M. Intravitreal triamcinolone for the treatment of diabetic macular edema. Curr Diabetes Rev 2006; 2: 99-112.
19. Degenring RF, Kreissig I, Jonas JB. Intraocular triamcinolone for diffuse diabetic macular edema. Ophthalmologe 2004; 101: 251-254.
20. Jonas JB, Degenring RF, Kamppeter BA, Kreissig I, Akkoyun I. Duration of the effect of intravitreal triamcinolone acetonide as treatment for diffuse diabetic macular edema. Am J Ophthalmol 2004; 138: 158-160.
21. Ozkiris A, Evereklioglu C, Erkiliç K, Tamçelik N, Mirza E. Intravitreal triamcinolone acetonide injection as primary treatment for diabetic macular edema. Eur J Ophthalmol 2004; 14: 543-549.
22. Chan CK, Mohamed S, Shanmugam MP, Tsang CW, Lai TY, Lam DS. Decreasing efficacy of repeated intravitreal triamcinolone injections in diabetic macular oedema. Br J Ophthalmol 2006; 90: 1137-1141.
23. Jonas JB, Söfker A, Degenring R. Intravitreal triamcinolone acetonide as an additional tool in pars plana vitrectomy for proliferative diabetic retinopathy. Eur J Ophthalmol 2003; 13: 468-473.
24. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005; 333: 328-335.
25. Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, Sanchez JG, Wu L, Maia M, et al. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology 2007; 114: 743-750.
26. Patel JL, Hykin PG, Schadt M, Luong V, Fitzke F, Gregor ZJ. Diabetic macular oedema: pilot randomized trial of pars plana vitrectomy vs macular argon photocoagulation. Eye 2006; 20: 873-881.
27. La Heij EC, Hendrikse F, Kessels AG, Derhaag PJ. Vitrectomy results in diabetic macular oedema without evident vitreomacular traction. Graefes Arch Clin Exp Ophthalmol 2001; 239: 264-270.
28. Oshima Y, Ohji M, Tano Y. Surgical outcomes of 25-gauge transconjunctival vitrectomy combined with cataract surgery for vitreoretinal diseases. Ann Acad Med Singapore 2006; 35: 175-180.
29. Jaissle GB, Szurman P, Bartz-Schmidt KU. Ocular side effects and complications of intravitreal triamcinolone acetonide injection. Ophthalmologe 2004; 101:121-128.
30. Lecleire-Collet A, Offret O, Gaucher D, Audren F, Haouchine B, Massin P. Full-thickness macular hole in a patient with diabetic cystoid macular oedema treated by intravitreal triamcinolone injections. Acta Ophthalmol Scand 2007; 85: 795-798.
31. Gillies MC, Kuzniarz M, Craig J, Ball M, Luo W, Simpson JM. Intravitreal triamcinolone-induced elevated intraocular pressure is associated with the development of posterior subcapsular cataract. Ophthalmology 2005; 112: 139-143.
32. Moshfeghi DM, Kaiser PK, Scott IU, Sears JE, Benz M, Sinesterra JP, et al. Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol 2003; 136: 791-796.
33. Gupta OP, Weichel ED, Regillo CD, Fineman MS, Kaiser RS, Ho AC, et al. Postoperative complications associated with 25-gauge pars plana vitrectomy. Ophthalmic Surg Lasers Imaging 2007; 38: 270-275.
34. Doi N, Uemura A, Nakao K, Sakamoto T. Vitreomacular adhesion and the defect in posterior vitreous cortex visualized by triamcinolone-assisted vitrectomy. Retina 2005; 25: 742-745.
35. Steffánson E. The therapeutic effects of retinal laser treatment and vitrectomy. A theory based on oxygen and vascular phisiology. Acta Ophtalmol Scand 2001; 79: 435-440.
36. Itakura H, Kishi S, Kotajima N, Murakami M. Persistent secretion of vascular endothelial growth factor into the vitreous cavity in proliferative diabetic retinopathy after vitrectomy. Ophthalmology 2004; 111: 1880-1884.